Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Vercruysse

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Current HIV Research|March 11, 2014
HIV-1 Rev multimerization: mechanism and insightsThomas Vercruysse, Dirk Daelemans
The Journal of Biological Chemistry|April 22, 2010
An intrabody based on a llama single-domain antibody targeting the N-terminal alpha-helical multimerization domain of HIV-1 rev prevents viral productionThomas Vercruysse, Els Pardon, Els Vanstreels, et al.
Bio-Protocol|March 4, 2021
Quantitative Nucleocytoplasmic Transport Assays in Cellular Models of NeurodegenerationJoni Vanneste, Thomas Vercruysse, Philip Van Damme, et al.
International Journal of Molecular Sciences|February 15, 2022
The T850D Phosphomimetic Mutation in the Androgen Receptor Ligand Binding Domain Enhances Recruitment at Activation Function 2Christine Helsen, Tien Nguyen, Thomas Vercruysse, et al.
Biomedicines|May 28, 2022
Cellular Stress Induces Nucleocytoplasmic Transport Deficits Independent of Stress GranulesJoni Vanneste, Thomas Vercruysse, Steven Boeynaems, et al.
Antiviral Research|December 3, 2014
A stably expressed llama single-domain intrabody targeting Rev displays broad-spectrum anti-HIV activityEline Boons, Guangdi Li, Els Vanstreels, et al.
Scientific Reports|November 2, 2019
C9orf72-generated poly-GR and poly-PR do not directly interfere with nucleocytoplasmic transportJoni Vanneste, Thomas Vercruysse, Steven Boeynaems, et al.
Plos One|April 9, 2013
Mapping the binding interface between an HIV-1 inhibiting intrabody and the viral protein RevThomas Vercruysse, Eline Boons, Tom Venken, et al.
Chemistry & Biology|January 13, 2015
Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editingJasper E Neggers, Thomas Vercruysse, Maarten Jacquemyn, et al.
RNA Biology|March 2, 2011
Measuring cooperative Rev protein-protein interactions on Rev responsive RNA by fluorescence resonance energy transferThomas Vercruysse, Sonalika Pawar, Wim De Borggraeve, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Current HIV Research|March 11, 2014
HIV-1 Rev multimerization: mechanism and insightsThomas Vercruysse, Dirk Daelemans
The Journal of Biological Chemistry|April 22, 2010
An intrabody based on a llama single-domain antibody targeting the N-terminal alpha-helical multimerization domain of HIV-1 rev prevents viral productionThomas Vercruysse, Els Pardon, Els Vanstreels, et al.
Bio-Protocol|March 4, 2021
Quantitative Nucleocytoplasmic Transport Assays in Cellular Models of NeurodegenerationJoni Vanneste, Thomas Vercruysse, Philip Van Damme, et al.
International Journal of Molecular Sciences|February 15, 2022
The T850D Phosphomimetic Mutation in the Androgen Receptor Ligand Binding Domain Enhances Recruitment at Activation Function 2Christine Helsen, Tien Nguyen, Thomas Vercruysse, et al.
Biomedicines|May 28, 2022
Cellular Stress Induces Nucleocytoplasmic Transport Deficits Independent of Stress GranulesJoni Vanneste, Thomas Vercruysse, Steven Boeynaems, et al.
Antiviral Research|December 3, 2014
A stably expressed llama single-domain intrabody targeting Rev displays broad-spectrum anti-HIV activityEline Boons, Guangdi Li, Els Vanstreels, et al.
Scientific Reports|November 2, 2019
C9orf72-generated poly-GR and poly-PR do not directly interfere with nucleocytoplasmic transportJoni Vanneste, Thomas Vercruysse, Steven Boeynaems, et al.
Plos One|April 9, 2013
Mapping the binding interface between an HIV-1 inhibiting intrabody and the viral protein RevThomas Vercruysse, Eline Boons, Tom Venken, et al.
Chemistry & Biology|January 13, 2015
Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editingJasper E Neggers, Thomas Vercruysse, Maarten Jacquemyn, et al.
RNA Biology|March 2, 2011
Measuring cooperative Rev protein-protein interactions on Rev responsive RNA by fluorescence resonance energy transferThomas Vercruysse, Sonalika Pawar, Wim De Borggraeve, et al.
Pageof 4